Adjuvants for Leishmania vaccines: From models to clinical application

Frontiers in Immunology

Volumn 3, Issue JUN, 2012, Pages

  Raman, Vanitha S ^a   Duthie, Malcolm S ^a   Fox, Christopher B ^a   Matlashewski, Greg ^b   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Adjuvants; Leishmania; Vaccine

Indexed keywords

EID: 84874162243     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00144     Document Type: Review

References (220)

1. Achard, C., and Foix, C. (1916). Sur l'emploi des corps gras comme vehicules des vaccines microbiens. Comp. Rend. Soc. Biol. 79, 209-211.
2. Aebig, J. A., Mullen, G. E., Dobrescu, G., Rausch, K., Lambert, L., Ajose-Popoola, O., Long, C. A., Saul, A., and Miles, A. P. (2007). Formulation of vaccines containing CpG oligonu-cleotides and alum. J. Immunol. Methods 323, 139-146.
3. Aebischer, T., Wolfram, M., Patzer, S. I., Ilg, T., Wiese, M., and Overath, P. (2000). Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. Infect. Immun. 68, 1328-1336.
4. Afonso, L. C., Scharton, T. M., Vieira, L. Q., Wysocka, M., Trinchieri, G., and Scott, P. (1994). The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263, 235-237.
5. Agrawal, S., and Kandimalla, E. R. (2007). Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem. Soc. Trans. 35(Pt 6), 1461-1467.
6. Arevalo, I., Ward, B., Miller, R., Meng, T. C., Najar, E., Alvarez, E., Matlashewski, G., and Llanos-Cuentas, A. (2001). Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. 33, 1847-1851.
7. Armijos, R. X., Weigel, M. M., Aviles, H., Maldonado, R., and Racines, J. (1998). Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J. Infect. Dis. 177, 1352-1357.
8. Badaro, R., Lobo, I., Munos, A., Netto, E. M., Modabber, F., Campos-Neto, A., Coler, R. N., and Reed, S. G. (2006). Immunotherapy for drug-refractory mucosal leishmaniasis. J. Infect. Dis. 194,1151-1159.
9. Badiee, A., Jaafari, M. R., Khamesipour, A., Samiei, A., Soroush, D., Kheiri, M. T., Barkhordari, F., McMaster, W. R., and Mahboudi, F. (2009a). Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition. Colloids Surf. B Biointerfaces 74, 37-44.
10. Badiee, A., Jaafari, M. R., Khamesipour, A., Samiei, A., Soroush, D., Kheiri, M. T., Barkhordari, F., McMaster, W. R., and Mahboudi, E (2009b). The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63). Exp. Parasitol. 121, 362-369.
11. Ballas, Z. K., Krieg, A. M., Warren, T., Rasmussen, W., Davis, H. L., Wald-schmidt, M., andWeiner, G. J. (2001). Divergent therapeutic and immuno-logic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167,4878-4886.
12. Barry, M., and Cooper, C. (2007). Review of hepatitis B surface antigen-1018ISS adjuvant-containing vaccine safety and efficacy. Expert Opin. Biol. Ther.7, 1731-1737.
13. Belkaid, Y., Mendez, S., Lira, R., Kadambi, N., Milon, G., and Sacks, D. (2000). A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J. Immunol. 165, 969-977.
14. Belkaid, Y., Piccirillo, C. A., Mendez, S., Shevach, E. M., and Sacks, D. L. (2002a). CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420, 502-507.
15. Belkaid, Y., von Stebut, E., Mendez, S., Lira, R., Caler, E., Bertholet, S., Udey, M. C., and Sacks, D. (2002b). CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J. Immunol. 168,3992-4000.
16. Bertholet, S., Goto, Y., Carter, L., Bhatia, A., Howard, R. F., Carter, D., Coler, R. N., Vedvick, T. S., and Reed, S. G. (2009). Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27,7036-7045.
17. Bickels, J., Kollender, Y., Merinsky, O., and Meller, I. (2002). Coley's toxin: historical perspective. Isr. Med. Assoc. J.4,471-472.
18. Birnbaum, R., Haskell, J., Vanchinathan, V., Greger, S., Narayan, R., Chang, P.-L., Tran, T. A., Hickerson, S. M., Beverley, S. M., Wilson, M. E., Bruhn, K. W., and Craft, N. (2012). Killedbut metabolically active Leishmania as a novel whole-cell vaccine for visceral leishmaniasis. Clin. Vaccine Immunol. 19,490-498.
19. Brazolot Millan, C. L., Weeratna, R., Krieg, A. M., Siegrist, C. A., and Davis, H. L. (1998). CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. U.S.A. 95, 15553-15558.
20. Brewer, J. M., Conacher, M., Hunter, C. A., Mohrs, M., Brombacher, F., and Alexander, J. (1999). Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J. Immunol. 163, 6448-6454.
21. Buates, S., and Matlashewski, G. (1999). Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J. Infect. Dis. 179, 1485-1494.
22. Buates, S., and Matlashewski, G. (2001). Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis. Antimicrob. Agents Chemother. 45, 1137-1142.
23. Cabrera, M., Blackwell, J. M., Castes, M., Trujillo, D., Convit, J., and Shaw, M. A. (2000). Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunol. 22, 73-79.
24. Campos-Neto, A., Webb, J. R., Greeson, K., Coler, R. N., Skeiky, Y. A., and Reed, S. G. (2002). Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect. Immun. 70, 2828-2836.
25. Carneiro, L. A., Travassos, L. H., and Girardin, S. E. (2007). Nod-like receptors in innate immunity and inflammatory diseases. Ann. Med. 39, 581-593.
26. Castes, M., Moros, Z., Martinez, A., Trujillo, D., Castellanos, P. L., Rondon, A. J., and Convit, J. (1989). Cell-mediated immunity in localized cutaneous leishmaniasis patients before and after treatment with immunotherapy or chemotherapy. Parasite Immunol. 11, 211-222.
27. Central Drugs Standard Control Organization. (2010). Vaccine Registration Certificate Data from Jan 2009 to July 2010. Available at: http://www. cdsco.nic.in/html/vaccinemain.html.
28. Chakravarty, J., Kumar, S., Trivedi, S., Rai, V. K., Singh, A., Ashman, J. A., Laughlin, E. M., Coler, R. N., Kahn, S. J., Beckmann, A. M., Cowgill, K. D., Reed, S. G., Sundar, S., and Piazza, F. M. (2011). A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 29, 3531-3537.
29. Chan, S. H., Perussia, B., Gupta, J. W., Kobayashi, M., Pospísil, M., Young, H. A., Wolf, S. F., Young, D., Clark, S. C., and Trinchieri, G. (1991). Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J. Exp. Med. 173, 869-879.
30. Clements, D. E., Coller, B. A., Lieber-man, M. M., Ogata, S., Wang, G., Harada, K. E., Putnak, J. R., Ivy, J. M., McDonell, M., Bignami, G. S., Peters, I. D., Leung, J., Weeks-Levy, C., Nakano, E. T., and Humphreys, T. (2010). Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28, 2705-2715.
31. Cohen, J. (1995). IL-12 deaths: explanation and a puzzle. Science 270, 908.
32. Coler, R. N., Bertholet, S., Moutaftsi, M., Guderian, J. A., Windish, H. P., Baldwin, S. L., Laughlin, E. M., Duthie, M. S., Fox, C. B., Carter, D., Friede, M., Vedvick, T. S., and Reed, S. G. (2011). Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 6, e16333. doi: 10.1371/journal.pone.0016333.
33. Coler, R. N., Goto, Y., Bogatzki, L., Raman, V., and Reed, S. G. (2007). Leish-111f, a recombinant polypro-tein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect. Immun. 75, 4648-4654.
34. Coler, R. N., and Reed, S. G. (2005). Second-generation vaccines against leishmaniasis. Trends Parasitol. 21, 244-249.
35. Coler, R. N., Skeiky, Y. A., Bernards, K., Greeson, K., Carter, D., Cornellison, C. D., Modabber, F., Campos-Neto, A., and Reed, S. G. (2002). Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70,4215-4225.
36. Cooper, C. L., Davis, H. L., Morris, M. L., Efler, S. M., Adhami, M. A., Krieg, A. M., Cameron, D. W., and Heathcote, J. (2004a). CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol. 24, 693-701.
37. Cooper, C. L., Davis, H. L., Morris, M. L., Efler, S. M., Krieg, A. M., Li, Y., Laframboise, C., Al Adhami, M. J., Khaliq, Y., Seguin, I., and Cameron, D. W (2004b). Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22, 3136-3143.
38. Crompton, P. D., Mircetic, M., Weiss, G., Baughman, A., Huang, C. Y., Topham, D. J., Treanor, J. J., Sanz, I., Lee, E E., Durbin, A. P., Miura, K., Narum, D. L., Ellis, R. D., Malkin, E., Mullen, G. E., Miller, L. H., Martin, L. B., and Pierce, S. K. (2009). The TLR9 ligand CpG promotes the acquisition of Plasmod-ium falciparum-specific memory B cells in malaria-naive individuals. J. Immunol. 182,3318-3326.
39. Daneshvar, H., Molaei, M. M., Kami-abi, H., Burchmore, R., Hagan, P., and Stephen Phillips, R. (2010). Gentamicin-attenuated Leishmania infantum: cellular immunity production and protection of dogs against experimental canine leishmaniasis. Parasite Immunol. 32, 722-730.
40. Darrah, P. A., Hegde, S. T., Patel, D. T., Lindsay, R. W., Chen, L., Roed-erer, M., and Seder, R. A. (2010). IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J. Exp. Med. 207, 1421-1433.
41. Darrah, P. A., Patel, D. T., De Luca, P. M., Lindsay, R. W., Davey, D. F., Flynn, B. J., Hoff, S. T., Andersen, P., Reed, S. G., Morris, S. L., Roed-erer, M., and Seder, R. A. (2007). Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13, 843-850.
42. Davis, H. L., Weeratna, R., Wald-schmidt, T. J., Tygrett, L., Schorr, J., and Krieg, A. M. (1998). CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.J. Immunol. 160, 870-876.
43. Davoudi, N., Tate, C. A., Warburton, C., Murray, A., Mahboudi, F., and McMaster, W R. (2005). Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials. Vaccine 23, 1170-1177.
44. Desjeux, P. (2001). The increase in risk factors for leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg. 95, 239-243.
45. Didierlaurent, A. M., Morel, S., Lock-man, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., Larocque, D., Van Mechelen, M., and Garçon, N. (2009). AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183, 6186-6197.
46. Duthie, M. S., Raman, V. S., Piazza, E M., and Reed, S. G. (2012). The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine 30, 134-141.
47. Duthie, M. S., Windish, H. P., Fox, C. B., and Reed, S. G. (2011). Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239, 178-196.
48. Dynavax Technologies. (2010). Data from the Phase 1b Study of SD-101 in Treatment-naïve, Genotype 1 HCV Patients. Available at: http://www. dynavax.com/hepatitis_ct.html.
49. Eisenbarth, S. C., Colegio, O. R., O'Connor, W., Sutterwala, F. S., and Flavell, R. A. (2008). Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122-1126.
50. Fernandez-Botran, R., Chilton, P. M., Hondowicz, B. D., Vetvickova, J., Yan, J., Jones, W. III, and Scott, P. (1999). Regulation of the production of soluble IL-4 receptors in murine cutaneous leishmaniasis. The roles of IL-12 and IL-4. J. Leukoc. Biol. 66, 481-488.
51. Firooz, A., Khamesipour, A., Ghoorchi, M. H., Nassiri-Kashani, M., Eskan-dari, S. E., Khatami, A., Hoosh-mand, B., Gorouhi, F., Rashighi-Firoozabadi, M., and Dowlati, Y. (2006). Imiquimod in combinaion with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch. Dermatol. 142, 1575-1579.
52. Flynn, B., Wang, V., Sacks, D. L., Seder, R. A., and Verthelyi, D. (2005). Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynu-cleotides expressing CpG motifs. Infect. Immun. 73,4948-4954.
53. Fox, C. B., Dutill, T. S., Chesko, J., Anderson, R. C., Reed, S. G., and Vedvick, T. S. (2010a). Characterization of aluminum hydroxide gel and oil-in-water emulsion formulations containing CpG ODNs. Biopharm. Int. October, S14-S19.
54. Fox, C. B., Friede, M., Reed, S. G., and Ireton, G. C. (2010b). Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell. Biochem. 53,303-321.
55. Frazer, I. H., and Levin, M. J. (2011). Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer. Curr. Opin. Virol. 1,268-279.
56. Fukao, T., Tanabe, M., Terauchi, Y., Ota, T., Matsuda, S., Asano, T., Kad-owaki, T., Takeuchi, T., and Koyasu, S. (2002). PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3, 875-881.
57. Garidel, P., Rappolt, M., Schromm, A. B., Howe, J., Lohner, K., Andrä, J., Koch, M. H., and Brandenburg, K. (2005). Divalent cations affect chain mobility and aggregate structure of lipopolysaccharide from Salmonella minnesota reflected in a decrease of its biological activity. Biochim. Biophys. Acta 1715,122-131.
58. Gicheru, M. M., Olobo, J. O., Anjili, C. O., Orago, A. S., Modabber, F., and Scott, P. (2001). Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect. Immun. 69, 245-251.
59. Goto, Y., Bogatzki, L. Y., Bertholet, S., Coler, R. N., and Reed, S. G. (2007). Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 25, 7450-7458.
60. Greenblatt, C. L. (1980). The present and future of vaccination for cutaneous leishmaniasis. Prog. Clin. Biol. Res. 47, 259-285.
61. Gupta, R. K., Chang, A. C., Griffin, P., Rivera, R., and Siber, G. R. (1996). In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine 14, 1412-1416.
62. Gurunathan, S., Prussin, C., Sacks, D. L., and Seder, R. A. (1998). Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4, 1409-1415.
63. Gurunathan, S., Sacks, D. L., Brown, D. R., Reiner, S. L., Charest, H., Glaichenhaus, N., and Seder, R. A. (1997). Vaccination with DNA encoding the immunodomi-nant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186,1137-1147.
64. Handman, E. (2001). Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14, 229-243.
65. Handman, E., Symons, E M., Baldwin, T. M., Curtis, J. M., and Scheerlinck, J. P. (1995). Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect. Immun. 63, 4261-4267.
66. Heinzel, E P., Rerko, R. M., and Hujer, A. M. (1998). Underproduction of interleukin-12 in susceptible mice during progressive leishmaniasis is due to decreased CD40 activity. Cell. Immunol. 184, 129-142.
67. Heinzel, E P., Schoenhaut, D. S., Rerko, R. M., Rosser, L. E., and Gately, M. K. (1993). Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 177, 1505-1509.
68. Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., and Akira, S. (2002). Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3, 196-200.
69. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Mat-sumoto, M., Hoshino, K., Wagner, H., Takeda, K., and Akira, S. (2000). A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745.
70. Hennessy, E. J., Parker, A. E., and O'Neill, L. A. (2010). Targeting Toll-like receptors: emerging theraeutics? Nat. Rev. Drug Discov. 9, 293-307.
71. Hervas, J. A., Martin-Santiago, A., Hervás, D., Rojo, E., Mena, A., Rocamora, V., and Dueñas J. (2011). Old World Leishmania infan-tum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod. Pediatr. Infect. Dis. J. 31, 97-100.
72. Hilleman, M. R. (1966). Critical appraisal of emulsified oil adjuvants applied to viral vaccines. Prog. Med. Virol. 8, 131-182.
73. Hilleman, M. R. (1999). Personal historical chronicle of six decades of basic and applied research in virology, immunology, and vaccinology. Immunol. Rev. 170, 7-27.
74. Hondowicz, B. D., Park, A. Y., Elloso, M. M., and Scott, P. (2000). Maintenance of IL-12-responsive CD4+ T cells during a Th2 response in Leishmania major-infected mice. Eur. J. Immunol. 30,2007-2014.
75. Hondowicz, B. D., Scharton-Kersten, T. M., Jones, D. E., and Scott, P. (1997). Leishmania major-infected C3H mice treated with anti-IL-12 mAb develop but do not maintain a Th2 response. J. Immunol. 159, 5024-5031.
76. Hsieh, C. S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., and Murphy, K. M. (1993). Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260, 547-549.
77. Hui, G. S., and Hashimoto, C. N. (2008). Adjuvant formulations possess differing efficacy in the potenti-ation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment. Int. Immunophar-macol. 8,1012-1022.
78. Hutchins, A. S., Artis, D., Hendrich, B. D., Bird, A. P., Scott, P., and Reiner, S. L. (2005). Cutting edge: a critical role for gene silencing in preventing excessive type 1 immunity. J. Immunol. 175,5606-5610.
79. Ioannou, X. P., Gomis, S. M., Hecker, R., Babiuk, L. A., and van Drunen Littel-van den Hurk, S. (2003). Safety and efficacy of CpG-containing oligodeoxynucleotides as immunological adjuvants in rabbits. Vaccine 21, 4368-4372.
80. Janeway, C. A. Jr. (1989). Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54(Pt 1), 1-13.
81. Janeway, C. A. Jr., and Medzhitov, R. (2002). Innate immune recognition. Annu. Rev. Immunol. 20, 197-216.
82. Jones, T. R., Obaldia, N. III, Gramzin-ski, R. A., Charoenvit, Y., Kolodny, N., Kitov, S., Davis, H. L., Krieg, A. M., and Hoffman, S. L. (1999). Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a pep-tide malaria vaccine in Aotus monkeys. Vaccine 17, 3065-3071.
83. Kahl, L. P., Scott, C. A., Lelchuk, R., Gre-goriadis, G., and Liew, E Y (1989). Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization. J. Immunol. 142, 4441-4449.
84. Kamil, A. A., Khalil, E. A., Musa, A. M., Modabber, F., Mukhtar, M. M., Ibrahim, M. E., Zijlstra, E. E., Sacks, D., Smith, P. G., Zicker, F., and El-Hassan, A. M. (2003). Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans. R. Soc. Trop. Med. Hyg. 97, 365-368.
85. Kane, M. M., and Mosser, D. M. (2001). The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166, 1141-1147.
86. Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R., Stewart, S., Alam, M., Kwissa, M., Villinger, F., Murthy, N., Steel, J., Jacob, J., Hogan, R. J., García-Sastre, A., Compans, R., and Pulendran, B. (2011). Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543-547.
87. Kawai, T., and Akira, S. (2007). TLR signaling. Semin. Immunol. 19, 24-32.
88. Kedzierski, L., Curtis, J. M., Doherty, P. C., Handman, E., and Kedzierska, K. (2008). Decreased IL-10 and IL-13 production and increased CD44hi T cell recruitment contribute to Leishmania major immunity induced by non-persistent parasites. Eur. J. Immunol. 38,3090-3100.
89. Kenney, R. T., Sacks, D. L., Sypek, J. P., Vilela, L., Gam, A. A., and Evans-Davis, K. (1999). Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 163,4481-4488.
90. Klinman, D. M., Kamstrup, S., Verthe-lyi, D., Gursel, I., Ishii, K. J., Takeshita, E, and Gursel, M. (2000). Activation of the innate immune system by CpG oligodeoxynucleotides: immunopro-tective activity and safety. Springer Semin. Immunopathol. 22, 173-183.
91. Klinman, D. M., Yamshchikov, G., and Ishigatsubo, Y. (1997). Contribution of CpG motifs to the immunogenic-ity of DNA vaccines. J. Immunol. 158, 3635-3639.
92. Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J., and Krieg, A. M. (1996). CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. U.S.A. 93, 2879-2883.
93. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., and Trinchieri, G. (1989). Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170, 827-845.
94. Kool, M., Soullie, T., van Nimwegen, M., Willart, M. A., Muskens, F., Jung, S., Hoogsteden, H. C., Hammad, H., and Lambrecht, B. N. (2008). Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205, 869-882.
95. Krieg, A. M. (2008). Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27, 161-167.
96. Krieg, A. M., Yi, A. K., Matson, S., Wald-schmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., and Klinman, D. M. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549.
97. Krug, A., Rothenfusser, S., Hornung, V., Jahrsdörfer, B., Blackwell, S., Bal-las, Z. K., Endres, S., Krieg, A. M., and Hartmann, G. (2001). Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 31, 2154-2163.
98. Kundi, M. (2007). New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev. Vaccines 6, 133-140.
99. Kuroda, E., Ishii, K. J., Uematsu, S., Ohata, K., Coban, C., Akira, S., Ari-take, K., Urade, Y., and Morimoto, Y. (2011). Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 34, 514-526.
100. Laabs, E. M., Wu, W., and Mendez, S. (2009). Vaccination with live Leishmania major and CpG DNA promotes interleukin-2 production by dermal dendritic cells and NK cell activation. Clin. Vaccine Immunol. 16, 1601-1606.
101. Lewis, P. A., and Dodge, E W. (1920). The sterilization of lipovaccines. J. Exp. Med. 31, 169-175.
102. Li, H., Nookala, S., and Re, E (2007). Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J. Immunol. 178, 5271-5276.
103. Li, H., Willingham, S. B., Ting, J. P., and Re, E (2008). Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181, 17-21.
104. Li, Y., Ishii, K., Hisaeda, H., Hamano, S., Zhang, M., Nakanishi, K., Yoshi-moto, T., Hemmi, H., Takeda, K., Akira, S., Iwakura, Y., and Himeno, K. (2004). IL-18 gene therapy develops Th1-type immune responses in Leishmania major-infected BALB/c mice: is the effect mediated by the CpG signaling TLR9? Gene Ther. 11, 941-948.
105. Liew, E Y., Li, Y., and Millott, S. (1990a). Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J. Immunol. 145,4306-4310.
106. Liew, E Y., Millott, S., Parkinson, C., Palmer, R. M., and Moncada, S. (1990b). Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J. Immunol. 144, 4794-4797.
107. Linghua, Z., Xingshan, T., and Fengzhen, Z. (2006). The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo. Int. Immunopharma-col. 6, 1267-1276.
108. Lipford, G. B., Bauer, M., Blank, C., Reiter, R., Wagner, H., and Heeg, K. (1997a). CpG-containing synthetic oligonucleotides promote B and cyto-toxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. I Immunol. 27, 2340-2344.
109. Lipford, G. B., Sparwasser, T., Bauer, M., Zimmermann, S., Koch, E. S., Heeg, K., and Wagner, H. (1997b). Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol. 27, 3420-3426.
110. Llanos-Cuentas, A., Calderon, W., Cruz, M., Ashman, J. A., Alves, E P., Coler, R. N., Bogatzki, L. Y., Bertholet, S., Laughlin, E. M., Kahn, S. J., Beck-mann, A. M., Cowgill, K. D., Reed, S. G., and Piazza, E M. (2010). A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine when used in combination with sodium stiboglu-conate for the treatment of mucosal leishmaniasis. Vaccine28,7427-7435.
111. Locksley, R. M., and Scott, P. (1991). Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function. Immunol. Today 12, A58-A61.
112. Lousada-Dietrich, S., Jogdand, P. S., Jepsen, S., Pinto, V. V., Ditlev, S. B., Christiansen, M., Larsen, S. O., Fox, C. B., Raman, V. S., Howard, R. F., Vedvick, T. S., Ireton, G., Carter, D., Reed, S. G., and Theisen, M. (2011). A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 29, 3284-3292.
113. Manetti, R., Parronchi, P., Giudizi, M. G., Piccinni, M. P., Maggi, E., Trinchieri, G., and Romag-nani, S. (1993). Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177, 1199-1204.
114. Marichal, T., Ohata, K., Bedoret, D., Mesnil, C., Sabatel, C., Kobiyama, K., Lekeux, P., Coban, C., Akira, S., Ishii, K. J., Bureau, F., and Desmet, C. J. (2011). DNA released from dying host cells mediates aluminum adjuvant activity. Nat. Med. 17, 996-1002.
115. Marrack, P., McKee, A. S., and Munks, M. W (2009). Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9, 287-293.
116. Masihi, K. N., Lange, W., Brehmer, W., and Ribi E. (1986). Immunobi-ological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects. Int. J. Immunophar-macol. 8, 339-345.
117. Mayrink,W., daCosta, C.A.,Magalhães, P. A., Melo, M. N., Dias, M., Lima, A. O., Michalick, M. S., and Williams, P. (1979). A field trial of a vaccine against American dermal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 73, 385-387.
118. Mazumdar, T., Anam, K., and Ali, N. (2005). Influence of phospho-lipid composition on the adju-vanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens. J. Parasitol. 91, 269-274.
119. Mazumder, S., Ravindran, R., Banerjee, A., and Ali, N. (2007). Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leish-manial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice. Vaccine 25, 8771-8781.
120. McGreal, E. P., Miller, J. L., and Gordon, S. (2005). Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr. Opin. Immunol. 17, 18-24.
121. McKenzie, A., Watt, M., and Git-tleson, C. (2010). ISCOMATRIX() vaccines: safety in human clinical studies. Hum. Vaccines 6, 237-246.
122. Medzhitov, R. (2009). Approaching the asymptote: 20 years later. Immunity 30,766-775.
123. Medzhitov, R., and Janeway, C. A. Jr. (2002). Decoding the patterns of self and nonself by the innate immune system. Science 296, 298-300.
124. Mendez, S., Gurunathan, S., Kamhawi, S., Belkaid, Y., Moga, M. A., Skeiky, Y A., Campos-Neto, A., Reed, S., Seder, R. A., and Sacks, D. (2001). The potency and durability of DNA-and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166,5122-5128.
125. Mendez, S., Reckling, S. K., Piccirillo, C. A., Sacks, D., and Belkaid, Y. (2004). Role for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J. Exp. Med. 200,201-210.
126. Mendez, S., Tabbara, K., Belkaid, Y., Bertholet, S., Verthelyi, D., Klin-man, D., Seder, R. A., and Sacks, D. L. (2003). Coinjection with CpG-containing immunostimula-tory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous leishmaniasis but maintains its potency and durability. Infect. Immun. 71, 5121-5129.
127. Metcalfe, I. C., and Gluck, R. (2006). "Virosomes for vaccine delivery," Immunopotentiators in Modern Vaccines, eds V. E. Schijns and D. O'Hagan (Burlington, MA: Elsevier Academic Press), 179-189.
128. Metzger, D. W. (2010). Interleukin-12 as an adjuvant for induction of protective antibody responses. Cytokine 52, 102-107.
129. Middleton, D., Rockman, S., Pearse, M., Barr, I., Lowther, S., Klippel, J., Ryan, D., and Brown, L. (2009). Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for pro -tective single-shot immunization. J. Virol. 83, 7770-7778.
130. Miranda-Verastegui, C., Llanos-Cuentas, A., Arévalo, I., Ward, B. J., and Matlashewski, G. (2005). Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin. Infect. Dis. 40, 1395-1403.
131. Miranda-Verastegui, C., Tulliano, G., Gyorkos, T. W., Calderon, W., Rahme, E., Ward, B., Cruz, M., Llanos-Cuentas, A., and Matlashewski, G. (2009). First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl. Trop. Dis. 3, e491. doi: 10.1371/journal.pntd.0000491.
132. Mohanan, D., Slutter, B., Henriksen-Lacey, M., Jiskoot, W., Bouwstra, J. A., Perrie, Y., Kündig, T. M., Gander, B., and Johansen, P. (2010). Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J. Control. Release 147, 342-349.
133. Moldoveanu, Z., Love-Homan, L., Huang, W Q., and Krieg, A. M. (1998). CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16, 1216-1224.
134. Momeni, A. Z., Jalayer, T., Emamjomeh, M., Khamesipour, A., Zicker, F., Ghassemi, R. L., Dowlati, Y., Sharifi, I., Aminjavaheri, M., Shafiei, A., Alimohammadian, M. H., Hashemi-Fesharki, R., Nasseri, K., Godal, T., Smith, P. G., and Modabber, F. (1999). A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17, 466-472.
135. Morein, B., Hu, K., Lövgren, K., and D'Hondt, E. (2007). "New ISCOMs meet unsettled vaccine demands," in Vaccine Adjuvants and Delivery Systems, ed. M. Singh (Hobo-ken, NJ: John Wiley & Sons, Inc.), 191-222.
136. Mougneau, E., Altare, F., Wakil, A. E., Zheng, S., Coppola, T., Wang, Z. E., Waldmann, R., Locksley, R. M., and Glaichenhaus, N. (1995). Expression cloning of a protective Leishmania antigen. Science 268, 563-566.
137. Mueller, M., Lindner, B., Kusumoto, S., Fukase, K., Schromm, A. B., and Seydel, U. (2004). Aggregates are the biologically active units of endotoxin. J. Biol Chem. 279,26307-26313.
138. Mullen, G. E., Aebig, J. A., Dobrescu, G., Rausch, K., Lambert, L., Long, C. A., Miles, A. P., and Saul, A. (2007). Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen. Vaccine 25, 5343-5347.
139. Mullen, G. E., Ellis, R. D., Miura, K., Malkin, E., Nolan, C., Hay, M., Fay, M. P., Saul, A., Zhu, D., Rausch, K., Moretz, S., Zhou, H., Long, C. A., Miller, L. H., and Treanor, J. (2008). Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falci-parum malaria. PLoS ONE 3, e2940. doi: 10.1371/journal.pone.0002940.
140. Musa, A. M., Khalil, E. A., Mah-goub, F. A., Elgawi, S. H., Modabber, F., Elkadaru, A. E., Aboud, M. H., Noazin, S., Ghalib, H. W., El-Hassan, A. M., and Leishmaniasis Research Group/Sudan. (2008). Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans. R. Soc. Trop. Med. Hyg. 102, 58-63.
141. Nadim, A., Javadian, E., Tahvildar-Bidruni, G., and Ghorbani, M. (1983). Effectiveness of leishman-ization in the control of cutaneous leishmaniasis. Bull Soc. Pathol Exot. Filiales 76, 377-383.
142. National Advisory Committee on Immunization. (2008). "Type and contents of vaccines currently approved for use in Canada," in 2006 Canadian Immunization Guide, 7th Edn. (Updated as of March 2008) (Ottawa: Public Health Agency of Canada).
143. O'Neill, L. A., and Bowie, A. G. (2007). The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7, 353-364.
144. Onomoto, K., Yoneyama, M., and Fujita, T. (2007). Regulation of antiviral innate immune responses by RIG-I family of RNA helicases. Curr. Top. Microbiol Immunol. 316, 193-205.
145. Othoro, C., Johnston, D., Lee, R., Soverow, J., Bystryn, J. C., and Nardin, E. (2009). Enhanced immunogenic-ity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod. Infect. Immun. 77, 739-748.
146. Ott, G., Singh, M., Kazzaz, J., Briones, M., Soenawan, E., Ugoz-zoli, M., and O'Hagan, D. T. (2002). A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. J. Control. Release 79, 1-5.
147. Owusu-Agyei, S., Ansong, D., Asante, K., Kwarteng Owusu, S., Owusu, R., Wireko Brobby, N. A., Dosoo, D., Osei Akoto, A., Osei-Kwakye, K., Adjei, E. A., Boahen, K. O., Sylverken, J., Adjei, G., Sambian, D., Apanga, S., Kayan, K., Vekemans, J., Ofori-Anyinam, O., Leach, A., Lievens, M., Demoitie, M. A., Dubois, M. C., Cohen, J., Ballou, W. R., Savarese, B., Chandramo-han, D., Gyapong, J. O., Milligan, P., Antwi, S., Agbenyega, T., Greenwood, B., and Evans, J. (2009). Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE 4, e7302. doi: 10.1371/journal. pone.0007302.
148. Papadopoulou, B., Roy, G., Breton, M., Kündig, C., Dumas, C., Fil-lion, I., Singh, A. K., Olivier, M., and Ouellette, M. (2002). Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect. Immun. 70, 62-68.
149. Papadopoulou, G., Karagouni, E., and Dotsika, E. (1998). ISCOMs vaccine against experimental leishmaniasis. Vaccine 16, 885-892.
150. Park, A. Y., Hondowicz, B. D., and Scott, P. (2000). IL-12 is required to maintain a Th1 response during Leishmania major infection. J. Immunol. 165, 896-902.
151. Pashine, A., Valiante, N. M., and Ulmer, J. B. (2005). Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11(Suppl.),S63-S68.
152. Persing, D. H., Coler, R. N., Lacy, M. J., Johnson, D. A., Baldridge, J. R., Hershberg, R. M., and Reed, S. G. (2002). Taking toll: lipid A mimetics as adjuvants and immunomodula-tors. Trends Microbiol. 10(Suppl.), S32-S37.
153. Pinoy, L. M. (1916a). Application a l'homme des vaccines en emulsion dans les corps gras (lipo-vaccins). C. R. Soc. Biol. 79, 352-354.
154. Pinoy, L. M. (1916b). Les vaccins en emulsion dans les corps gras ou'lipo-vaccins'. C. R. Soc. Biol. 79,201-203.
155. Poltorak, A., He, X., Smirnova, I., Liu, M. Y., Van Huffel, C., Du, X., Bird-well, D., Alejos, E., Silva, M., Galanos, C., Freudenberg, M., Ricciardi-Castagnoli, P., Layton, B., and Beutler B. (1998). Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088.
156. Probst, P., Skeiky, Y. A., Steeves, M., Ger-vassi, A., Grabstein, K. H., Reed, S. G. (1997). A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur. J. Immunol. 27, 2634-2642.
157. Querec, T., Bennouna, S., Alkan, S., Laouar, Y., Gorden, K., Flavell, R., Akira, S., Ahmed, R., and Pulen-dran, B. (2006). Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203,413-424.
158. Raman, V S., Bhatia, A., Picone, A., Whittle, J., Bailor, H. R., O'Donnell, J., Pattabhi, S., Guderian, J. A., Mohamath, R., Duthie, M. S., and Reed, S. G. (2010). Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J. Immunol. 185, 1701-1710.
159. Reed, S. G., Bertholet, S., Coler, R. N., and Friede, M. (2009). New horizons in adjuvants for vaccine development. Trends Immunol. 30, 23-32.
160. Reed, S. G., and Scott, P. (1993). T-cell and cytokine responses in leishmaniasis. Curr. Opin. Immunol. 5, 524-531.
161. Rhee, E. G., Mendez, S., Shah, J. A., Wu, C. Y., Kirman, J. R., Turon, T. N., Davey, D. F., Davis, H., Klin-man, D. M., Coler, R. N., Sacks, D. L., and Seder, R. A. (2002). Vaccination with heat-killed leishmania antigen or recombinant leishma-nial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J. Exp. Med. 195, 1565-1573.
162. Ribi, E., Cantrell, J. L., Takayama, K., Qureshi, N., Peterson, J., and Ribi, H. O. (1984). Lipid A and immunother-apy. Rev. Infect. Dis. 6, 567-572.
163. Richards, R. L., Swartz, G. M. Jr., Schultz, C., Hayre, M. D., Ward, G. S., Ballou, W. R., Chulay, J. D., Hock-meyer, W. T., Berman, S. L., and Alving, C. R. (1989). Immunogenic-ity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A. Vaccine 7, 506-512.
164. Row, R. (1912). The curative value of Leishmania culture "vaccine" in oriental sore. Br. Med. J. 1, 540-541.
165. Salem, A. K., and Weiner, G. J. (2009). CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies. Adv. Drug Deliv. Rev. 61, 193-194.
166. Scharton-Kersten, T., Afonso, L. C., Wysocka, M., Trinchieri, G., and Scott, P. (1995). IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J. Immunol. 154, 5320-5330.
167. Schijns, V. E. (2000). Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. 12, 456-463.
168. Scott, P. (1991). Host and parasite factors regulating the development of CD4+ T-cell subsets in experimental cutaneous leishmaniasis. Res. Immunol. 142, 32-36.
169. Scott, P. (1993). IL-12: initiation cytokine for cell-mediated immunity. Science 260,496-497.
170. Scott, P. (1998). Differentiation, regulation, and death of T helper cell subsets during infection with Leishmania major. Immunol. Res. 17, 229-238.
171. Scott, P., and Trinchieri, G. (1997). IL-12 as an adjuvant for cell-mediated immunity. Semin. Immunol. 9, 285-291.
172. Seubert, A., Monaci, E., Pizza, M., O'Hagan, D. T., and Wack, A. (2008). The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180, 5402-5412.
173. Sharifi, I., FeKri, A. R., Aflatonian, M. R., Khamesipour, A., Nadim, A., Mousavi, M. R., Momeni, A. Z., Dowlati, Y., Godal, T., Zicker, E, Smith, P. G., and Modabber, F. 1998). Randomised vaccine trial of single dose of killed Leishma nia major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351,1540-1543.
174. Shimizu, Y., Takagi, H., Nakayama, T., Yamakami, K., Tadakuma, T., Yokoyama, N., and Kojima, N. (2007). Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishma-nial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages. Parasite Immunol. 29, 229-239.
175. Singh, M., Chesko, J., Kazzaz, J., Ugo-zolli, M., Malyala, P., and O'Hagan, D. T. (2007). "Surface-charged poly(lactide-co-glycolide) micropar-ticles as novel antigen delivery systems," Vaccine Adjuvants and Delivery Systems, ed. M. Singh (Hoboken, NJ: John Wiley & Sons), 223-248.
176. Sjolander, A., Baldwin, T. M., Curtis, J. M., Bengtsson, K. L., and Hand-man, E. (1998a). Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 16, 2077-2084.
177. Sjolander, A., Baldwin, T. M., Curtis, J. M., and Handman, E. (1998b). Induction of aTh1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis.J. Immunol. 160,3949-3957.
178. Skeiky, Y. A., Benson, D. R., Costa, J. L., Badaro, R., and Reed, S. G. (1997). Association of Leishmania heat shock protein 83 antigen and immunoglob-ulin G4 antibody titers in Brazilian patients with diffuse cutaneous leishmaniasis. Infect. Immun. 65, 5368-5370.
179. Skeiky, Y. A., Benson, D. R., Guderian, J. A., Whittle, J. A., Bacelar, O., Car-valho, E. M., and Reed, S. G. (1995a). Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect. Immun. 63, 4105-4114.
180. Skeiky, Y. A., Guderian, J. A., Benson, D. R., Bacelar, O., Carvalho, E. M., Kubin, M., Badaro, R., Trinchieri, G., and Reed, S. G. (1995b). A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J. Exp. Med. 181, 1527-1537.
181. Skeiky, Y. A., Kennedy, M., Kaufman, D., Borges, M. M., Guderian, J. A., Scholler, J. K., Ovendale, P. J., Picha, K. S., Morrissey, P. J., Grabstein, K. H., Campos-Neto, A., and Reed, S. G. (1998). LeIF: a recombinant Leishmania protein that induces an IL-12-mediatedTh1 cytokine profile. J. Immunol. 161, 6171-6179.
182. Skidmore, B. J., Chiller, J. M., Wei-gle, W. O., Riblet, R., and Watson, J. (1976). Immunologic properties of bacterial lipopolysaccharide (LPS). III. Genetic linkage between the in vitro mitogenic and in vivo adjuvant properties of LPS. J. Exp. Med. 143, 143-150.
183. Soudi, S., Hosseini, A. Z., and Hashemi, S. M. (2011). Co-administration of rectal BCG and autoclaved Leishmania major induce protection in susceptible BALB/c mice. Parasite Immunol. 33, 561-571.
184. Stacey, K. J., and Blackwell, J. M. (1999). Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect. Immun. 67, 3719-3726.
185. Stenger, S., Thuring, H., Röllinghoff, M., and Bogdan, C. (1994). Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J. Exp. Med. 180, 783-793.
186. Stobie, L., Gurunathan, S., Prussin, C., Sacks, D. L., Glaichenhaus, N., Wu, C. Y., and Seder, R. A. (2000). The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc. Natl. Acad. Sci. U.S.A. 97, 8427-8432.
187. Sun, H. X., Xie, Y., and Ye, Y. P. (2009). ISCOMs and ISCOMATRIX. Vaccine 27, 4388-4401.
188. Sypek, J. P., Chung, C. L., Mayor, S. E., Subramanyam, J. M., Goldman, S. J., Sieburth, D. S., Wolf, S. F., and Schaub, R. G. (1993). Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J. Exp. Med. 177, 1797-1802.
189. Tafaghodi, M., Khamesipour, A., and Jaafari, M. R. (2011). Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN. Parasitol. Res. 108, 1265-1273.
190. Takayama, K., Qureshi, N., Mascagni, P., Nashed, M. A., Anderson, L., and Raetz, C. R. (1983). Fatty acyl derivatives of glucosamine 1-phosphate in Escherichia coli and their relation to lipid A. Complete structure of A diacyl GlcN-1-P found in a phosphatidylglycerol-deficient mutant. J. Biol. Chem. 258, 7379-7385.
191. Testerman, T. L., Gerster, J. F., Imbert-son, L. M., Reiter, M. J., Miller, R. L., Gibson, S. J., Wagner, T. L., and Tomai, M. A. (1995). Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leukoc. Biol. 58, 365-372.
192. The European Medicines Agency. (2005). Guideline on Adjuvants in Vaccines for Human Use. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003809.pdf.
193. The Working Group on Research Priorities for Development of Leishmaniasis Vaccines, Costa, C. H., Peters, N. C., Maruyama, S. R., de Brito, E. C. Jr., and Santos, I. K. (2011). Vaccines for the leishmaniases: proposals for a research agenda. PLoS Negl. Trop. Dis. 5, e943. doi: 10.1371/jour-nal.pntd.0000943.
194. Titus, R. G., Gueiros-Filho, F. J., de Freitas, L. A., and Beverley, S. M. (1995). Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. U.S.A. 92, 10267-10271.
195. Tokunaga, T. (1980). [A review on mechanism of anti-tumor action of BCG (author's transl)]. Kekkaku 55, 351-357.
196. Tokunaga, T., Yamamoto, T., and Yamamoto, S. (1999). How BCG led to the discovery of immunostimulatory DNA. Jpn. J. Infect. Dis. 52, 1-11.
197. Tonui, W K., Mejia, J. S., Hochberg, L., Mbow, M. L., Ryan, J. R., Chan, A. S., Martin, S. K., and Titus, R. G. (2004). Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major. Infect. Immun. 72, 5654-5661.
198. Traore, B., Kone, Y., Doumbo, S., Doumtabé, D., Traoré, A., Cromp-ton, P. D., Mircetic, M., Huang, C. Y., Kayentao, K., Dicko, A., Sagara, I., Ellis, R. D., Miura, K., Guindo, A., Miller, L. H., Doumbo, O. K., and Pierce, S. K. (2009). The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium fal-ciparum-specific memory B cells in semi-immune adults in Mali. Vaccine 27, 7299-7303.
199. U.S. Food and Drug Administration. (2011). Complete List of Vaccines Licensed for Immunization and Distribution in the US. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833.
200. Uzonna, J. E., Spath, G. F., Beverley, S. M., and Scott P. (2004). Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol. 172, 3793-3797.
201. Velez, I. D., Gilchrist, K., Martínez, S., Ramírez-Pineda, J. R., Ashman, J. A., Alves, F. P., Coler, R. N., Bogatzki, L. Y., Kahn, S. J., Beckmann, A. M., Cowgill, K. D., Reed, S. G., and Piazza, E M. (2009). Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 28, 329-337.
202. von Stebut, E., Belkaid, Y., Jakob, T., Sacks, D. L., and Udey, M. C. (1998). Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J. Exp. Med. 188,1547-1552.
203. Wack, A., Baudner, B. C., Hilbert, A. K., Manini, I., Nuti, S., Tavarini, S., Scheffczik, H., Ugozzoli, M., Singh, M., Kazzaz, J., Montomoli, E., Del Giudice, G., Rappuoli, R., and O'Hagan, D. T. (2008). Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26, 552-561.
204. Wagner, T. L., Ahonen, C. L., Couture, A. M., Gibson, S. J., Miller, R. L., Smith, R. M., Reiter, M. J., Vasilakos, J. P., and Tomai, M. A. (1999). Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell. Immunol. 191, 10-19.
205. Walker, P. S., Scharton-Kersten, T., Krieg, A. M., Love-Homan, L., Row-ton, E. D., Udey, M. C., and Vogel, J. C. (1999). Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc. Natl. Acad. Sci. U.S.A. 96, 6970-6975.
206. Webb, J. R., Campos-Neto, A., Skeiky, Y. A., and Reed, S. G. (1997). Molecular characterization of the heat-inducible LmSTI1 protein of Leishmania major. Mol. Biochem. Parasitol. 89, 179-193.
207. Webb, J. R., Kaufmann, D., Campos-Neto, A., and Reed, S. G. (1996). Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 157, 5034-5041.
208. Wenyon, C. M. (1928). Kala-azar and oriental sore: the problem of transmission. Br. Med. J. 2, 558-562.
209. White, R. G., Coons, A. H., and Connolly, J. M. (1955). Studies on antibody production. III. The alum granuloma. J. Exp. Med. 102, 73-82.
210. Whitmore, E. R. (1919). Lipovac-cines, with special reference to public health work. Am. J. Public Health 9, 504-507.
211. WHO. (2004). 13 Vaccines that are in Common Use in Most Developing Countries. Available at: http://www.who.int/vaccines-documents/DoxTrng/h4iip.htm.
212. WHO. (2010). "Control of the leishma-niases," in Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. WHO Technical Report Series 949.
213. WHO Department of Immunization, Vaccines and Biologicals and UNICEF Programme Division, Health Section. (2005). Global Immunization Vision and Strategy 2006-2015. Available at: http://whqlibdoc.who.int/hq/2005/WHO_IVB_05.05.pdf.
214. Wooldridge, J. E., Ballas, Z., Krieg, A. M., and Weiner, G. J. (1997). Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89,2994-2998.
215. Wright, A. K., Briles, D. E., Metzger, D. W., and Gordon, S. B. (2008). Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection. Vaccine 26, 4893-4903.
216. Wu, W., Huang, L., and Mendez, S. (2010). A live Leishmania major vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL/6 mice. Eur. J. Immunol. 40, 2517-2527.
217. Wu, W., Weigand, L., Belkaid, Y., and Mendez, S. (2006). Immunomodu-latory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides. Eur. J. Immunol. 36, 3238-3247.
218. Yang, Z., Zhang, X., Darrah, P. A., and Mosser, D. M. (2010). The regulation of Th1 responses by the p38 MAPK. J. Immunol. 185, 6205-6213.
219. Zhang, W W., and Matlashewski, G. (2008). Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect. Immun. 76, 3777-3783.
220. Zimmermann, S., Egeter, O., Haus-mann, S., Lipford, G. B., Röcken, M., Wagner, H., and Heeg, K. (1998). CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 160, 3627-3630.